Anti-Coagulants - India
India- In India, the Anti-Coagulants market is forecasted to achieve a revenue of INR US$312.60m by 2024.
- It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 8.15%, leading to a market volume of INR US$462.70m by 2029.
- Comparing globally, United States is projected to generate the highest revenue of US$16.74bn in 2024.
- India is experiencing a growing demand for anti-coagulants as the population ages and the prevalence of cardiovascular diseases increases.
- Key regions:
- Australia,
- Japan,
- United States,
- Germany,
- Europe
Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson
In-Scope
- Blood clotting inhibitors
Out-Of-Scope
- Anti-fibrinolytics
- Anti-hypertensives
- Other hematology drugs
- Other anti-thrombotic agents, such as platelet aggregation inhibitors
- Thrombolytic drugs
